Subpopulation profile of CD34+ pluripotent hematopoietic stem cells in blood malignancies
- Authors: Pashkina E.A.1, Aktanova A.A.1, Bykova M.V.1, Skachkov I.P.1, Pronkina N.V.1, Denisova V.V.1, Kozlov V.A.1
-
Affiliations:
- Research Institute of Fundamental and Clinical Immunology
- Issue: Vol 28, No 3 (2025)
- Pages: 805-810
- Section: SHORT COMMUNICATIONS
- URL: https://journals.rcsi.science/1028-7221/article/view/319938
- DOI: https://doi.org/10.46235/1028-7221-17198-SPO
- ID: 319938
Cite item
Full Text
Abstract
The incidence of malignant blood diseases has been steadily increasing over past decades. Unlike many other types of malignant neoplasms, blood cancers often occur at a young age, being also the main cause of death among all hematopoietic disorders in pediatric patients. Mutation events in hematopoietic stem cells are the cause of blood cancers which subsequently lead to increasimg number of tumor clones and displacement of healthy cells in the niches they occupy thus leading to a number of changes in blood and bone marrow, including irreversible ones. The aim of this study was to assess the subpopulation composition of pluripotent hematopoietic stem cells in patients with blood cancers and healthy donors. The study included patients with blood cancers (n = 13), including acute lymphoblastic leukemia (ALL; n = 3), acute myeloid leukemia (AML; n = 3), and multiple myeloma (MM; n = 7), as well as healthy donors (n = 4). The phenotypic composition of hematopoietic CD34+CD38- pluripotent cells was assessed by flow cytometry using the following monoclonal antibodies: CD34 APC (BioLegend, USA), CD38 PE-Cy7 (ElabScience, China), CD45RA PerCP (ElabScience, China), CD90 APC-Cy7 (Cloud-Clone Corp., USA), Lin- (cocktail CD3/14/16/19/20/56) FITC (BioLegend, USA). The following populations were assessed: hematopoietic stem cells (Lin-CD34+CD38-CD45RA-CD90+) and pluripotent progenitors (Lin-CD34+CD38-CD45RA-CD90-). In patients with hemoblastoses, the relative number of cells with Lin-CD34+CD38-CD45RA-CD90+ phenotype proved to be increased, thus corresponding to hematopoietic stem cells, but not pluripotent progenitor cells. At the same time, the number of pluripotent progenitor cells tended to decrease in acute myeloid leukemia. We have observed some changes in the subpopulation composition of pluripotent hematopoietic stem cells in patients with blood cancers, when compared with healthy donors.
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina A. Pashkina
Research Institute of Fundamental and Clinical Immunology
Author for correspondence.
Email: pashkina.e.a@yandex.ru
ORCID iD: 0000-0002-4912-5512
PhD (Biology), Head, Laboratory of Clinical Immunopathology
Russian Federation, 14 Yadrintsevskaya St, Novosibirsk, 630099Alina A. Aktanova
Research Institute of Fundamental and Clinical Immunology
Email: aktanova_al@mail.ru
Researcher, Laboratory of Clinical Immunopathology
Russian Federation, 14 Yadrintsevskaya St, Novosibirsk, 630099Maria V. Bykova
Research Institute of Fundamental and Clinical Immunology
Email: maria18021997@mail.ru
Junior Researcher, Laboratory of Clinical Immunopathology
Russian Federation, 14 Yadrintsevskaya St, Novosibirsk, 630099Ivan P. Skachkov
Research Institute of Fundamental and Clinical Immunology
Email: ivanskachkov02@gmail.com
Laboratory Assistant, Laboratory of Clinical Immunopathology
Russian Federation, 14 Yadrintsevskaya St, Novosibirsk, 630099Natalya V. Pronkina
Research Institute of Fundamental and Clinical Immunology
Email: fake@neicon.ru
PhD (Medicine), Head, Laboratory of Clinical Immunology
Russian Federation, 14 Yadrintsevskaya St, Novosibirsk, 630099Vera V. Denisova
Research Institute of Fundamental and Clinical Immunology
Email: verden@bk.ru
PhD (Medicine), Head, Department of Hematology
Russian Federation, 14 Yadrintsevskaya St, Novosibirsk, 630099Vladimir A. Kozlov
Research Institute of Fundamental and Clinical Immunology
Email: vakoz40@yandex.ru
PhD, MD (Medicine), Professor, Full Member, Russian Academy of Sciences, Scientific Director
Russian Federation, 14 Yadrintsevskaya St, Novosibirsk, 630099References
- Литвицкий П.Ф., Жевак Т.Н. Гемобластозы. Лейкозы лимфоидного происхождения // Вопросы современной педиатрии. 2016. Т. 15, № 5. С. 457-470. [Litvitsky P.F., Zhevak T.N. Hematological malignancies. lymphocytic leukaemia. Voprosy sovremennoy pediatrii = Current Pediatrics, 2016, Vol. 15, no. 5, pp. 457-470. (In Russ.)]
- Мовчан Л.В., Шман Т.В. Анализ количества клеток с фенотипом CD34+CD38- и CD34+CD38-CD19+ в качестве потенциальных лейкемических стволовых клеток при остром лимфобластном лейкозе у детей // Проблемы здоровья и экологии, 2011. №2S. С. 66-69. [Movchan L.V., Shman T.V. Analysis of the number of cells with CD34+CD38- and CD34+CD38-CD19+ phenotypes as potential leukemic stem cells in acute lymphoblastic leukemia in children. Problemy zdorovya i ekologii = Health and Ecology Issues, 2011, no. 2S, pp. 66-69. (In Russ.)]
- Ругаль В.И., Бессмельцев С.С., Семенова Н.Ю., Грицаев С.В., Кострома И.И., Енукашвили Н.И., Чубарь А.В., Иволгин Д.А. Характеристика микроокружения костного мозга при множественной миеломе до и после терапии // Сибирский научный медицинский журнал, 2019. Т. 39, № 1. С. 112-118. [Rugal V.I., Bessmeltsev S.S., Semenova N.Yu., Gritsaev S.V., Kostroma I.I., Enukashvili N.I., Chubar A.V., Ivolgin D.A. Characteristics of bone marrow microenvironment in multiple myeloma before and after treatment. Sibirskiy nauchnyy meditsinskiy zhurnal = Siberian Scientific Medical Journal, 2019, Vol. 39, no. 1, pp. 112-118. (In Russ.)]
- Christopherson K.W., Paganessi L.A., Rhoades D.R., Dillon H.M., Gezer S., Larson M.L., Fung H.C., Gregory S.A. Abnormally high levels of circulating CD34+CD38-, CD34+CD38+, and CD10+ hematopoietic stem and progenitor cells in the peripheral blood of B-cell chronic lymphocytic leukemia (B-CLL) patients suggest the presence of additional therapeutic target cells. Blood, 2007, Vol. 110, no. 11, 4711. doi: 10.1182/blood.V110.11.4711.4711.
- Dander E., Palmi C., D’Amico G., Cazzaniga G. The bone marrow niche in B-cell acute lymphoblastic leukemia: the role of microenvironment from pre-leukemia to overt leukemia. Int. J. Mol. Sci., 2021, Vol. 22, no. 9, 4426. doi: 10.3390/ijms22094426.
- Reuvekamp T., Ngai L.L., den Hartog D., Carbaat-Ham J., Fayed M.M.H.E., Scholten W.J., Mocking T.R., Chitu D.A., Pabst T., Klein S.K., Stussi G., Griskevicius L., Breems D., van Lammeren-Venema D., Boersma R., Ossenkoppele G.J., van de Loosdrecht A.A., Bachas C., Huls G., de Leeuw D.C., Cloos J. CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents. Leukemia, 2025, Vol. 39, no. 4. pp. 972-975.
- Zeijlemaker W., Grob T., Meijer R., Hanekamp D., Kelder A., Carbaat-Ham J.C., Oussoren-Brockhoff Y.J.M., Snel A.N., Veldhuizen D., Scholten W.J., Maertens J., Breems D.A., Pabst T., Manz M.G., van der Velden V.H.J., Slomp J., Preijers F., Cloos J., van de Loosdrecht A.A., Löwenberg B., Valk P.J.M., Jongen-Lavrencic M., Ossenkoppele G.J., Schuurhuis G.J. CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia, 2019, Vol. 33, no. 5. pp. 1102-1112.
- Zhang N., Wu J., Wang Q., Liang Y., Li X., Chen G., Ma L., Liu X., Zhou F. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J., 2023, Vol. 13, no. 1. 82. doi: 10.1038/s41408-023-00853-3.
Supplementary files
